This was corroborated by experiments using mouse melanoma cells genetically engineered to lack Gpx4. The targeted knockout of Gpx4 decreased the percentage of mice with formed metastatic tumors after intravenous injection of Gpx4-deleted melanoma cells, but not after intranodal injection. This evidence concerns the gene GPX4 and metastatic neoplasm.